Search
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production.
Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL)Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigational[L1737] The U.S. … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.
Synonyms: Moab, chimeric, SGN-30, to CD30 antigenTrolamine
go.drugbank.com/drugs/DB13747ApprovedInvestigationalTrolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines. … Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174].
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalCinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting … centre of the hypothalamus.
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalOn February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … of the mitogen-activated protein kinase (MAPK) pathway.
Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational(NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Gadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigationalEthoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists